Form 4: Pacira BioSciences Director Acquires 1,400 Shares of Common Stock
SEC Form 4 Filing
Mark Froimson, a director of Pacira BioSciences, Inc., purchased 1,400 shares of common stock at a price of $11.58 per share on August 12, 2024.
Summary
- On August 12, 2024, Mark Froimson, a director of Pacira BioSciences, Inc. (PCRX), acquired 1,400 shares of common stock.
- The purchase price was $11.58 per share.
- Following the transaction, Froimson directly owns 14,473 shares of Pacira BioSciences common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares is generally a good sign, but the quantity is not large enough to be a major market mover.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of insider trading activity and are closely watched by investors for signals about a company's prospects. Director purchases are generally viewed more favorably than sales.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of the transaction: Mark Froimson purchased 1,400 shares of Pacira BioSciences common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.